Market Overview

The Week Ahead In Biotech: ASCO Presentations In The Spotlight

The Week Ahead In Biotech: ASCO Presentations In The Spotlight

Biotech stocks closed the week ended May 22 higher, with stray clinical readouts and COVID-19 drug- and vaccine-related news moving stocks in the sector.

Surface Oncology Inc (NASDAQ: SURF) was one of the biggest advancers of the week after it announced an oncology partnership with Merck & Co., Inc. (NYSE: MRK).

Sorrento Therapeutics Inc (NASDAQ: SRNE), which announced on May 15 the discovery of 100%  inhibition of SARS-CoV-2, was in the news yet again this week as short sellers clamped down on the biotech, questioning the veracity of its claims.

AstraZeneca plc (NYSE: AZN) and Merck received the FDA nod for Lynparza to treat metastatic castration-resistant prostate cancer with homologous recombination repair mutations.

The following are key catalysts for the unfolding week:


2020 International Society of Cell and Gene Therapy, or ISCT, annual meeting: May 28-29.
American Society of Clinical Oncologists 2020 Virtual Scientific Program: May 29-31. 
American Society for Clinical Pathology, or ASCP, 2020 Annual Meeting (virtual conference): May 29-30. 


Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Sanofi SA (NASDAQ: SNY) await the FDA verdict on their sBLA for Dupixent in pediatric eczema. (Tuesday)

Clinical Readouts

Mersana Therapeutics Inc (NASDAQ: MRSN) will present interim data from the ongoing XMT-1536 Phase 1 dose expansion in patients with ovarian cancer and non-small cell lung adenocarcinoma.

See also: These 6 Coronavirus Vaccine Candidates Are The Likeliest To Succeed, Says Morgan Stanley

ASCO Presentations


  • Arvinas Inc (NASDAQ: ARVN): additional Phase 1 data on ARV-110 in castration-resistant prostate cancer
  • Trillium Therapeutics Inc (NASDAQ: TRIL): updated Phase 1a/b data on TTI-622 in refractory lymphoma or multiple myeloma
  • Cardiff Oncology Inc (NASDAQ: CRDF): Phase 1b/2 data on onvansertib, folfiri and avastin in KRAS-mutated colorectal cancer
  • Iovance Biotherapeutics Inc (NASDAQ: IOVA): new interim Phase 2 data on LN-144-lifileucel in refractory metastatic melanoma
  • Blueprint Medicines Corp (NASDAQ: BPMC): updated Phase 1/2 data for praksetinib in RET-altered tumors
  • Allogene Therapeutics Inc (NASDAQ: ALLO): Initial Phase 1 data for ALLO-501 in non-Hodgkin lymphoma
  • Deciphera Pharmaceuticals Inc (NASDAQ: DCPH): Phase 1b/2 data on rebastinib and paclitaxel in solid tumors
  • GENMAB A/S/S ADR (NASDAQ: GMAB): Phase 1/2 data on epcoritamab in B-cell lymphoma
  • AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO): Phase 3 data for tivozanib in third-line treatment of patients with renal cell cancer
  • Merck: Phase 3 data for Keytruda in colorectal cancer
  • Amgen, Inc. (NASDAQ: AMGN): updated Phase 1 data for AMG 510 in solid tumors
  • IMMUTEP LTD/S ADR (NASDAQ: IMMP): initial Phase 2 data for eftilagimod alpha and Keytruda in non-small cell lung cancer, head and neck cancer
  • Heat Biologics Inc (NASDAQ: HTBX): Phase 2 data on HS-110 and Opdivo in non-small cell lung cancer
  • Autolus Therapeutics Ltd – ADR (NASDAQ: AUTL): updated Phase 2 data for AUTO3 in relapsed or refractory diffuse large B-cell lymphoma
  • Oncolytics Biotech, Inc. (NASDAQ: ONCY): interim Phase 1 data for pelareorep and carfilzomib/dexamethasone in multiple myeloma; interim Phase 2 data for pelareorep with Keytruda in pancreatic cancer
  • Athenex Inc (NASDAQ: ATNX): Phase 2 data on oraxol in angiosarcoma
  • Harpoon Therapeutics Inc (NASDAQ: HARP): preliminary Phase 1 data on HPN424 in metastatic castration-resistant prostate cancer
  • Gossamer Bio Inc (NASDAQ: GOSS): initial Phase 1/2 data on GB1275 in solid tumors
  • ImmunoGen, Inc (NASDAQ: IMGN): initial Phase 1b/2 data for mirvetuximab soravtansine in ovarian cancer and relapsed endometrial cancer
  • Merus NV (NASDAQ: MRUS): Phase 2 data for MCLA-128 in breast cancer
  • CytomX Therapeutics Inc (NASDAQ: CTMX): Phase 1 data for CX-2029 in solid tumors/diffuse large B-cell lymphoma; initial Phase 1 data on BMS-986249 and Opdivo in solid tumors or lymphomas
  • Corvus Pharmaceuticals Inc (NASDAQ: CRVS): initial Phase 1b/2 data for CPI-444 in solid tumors
  • Pfizer Inc. (NYSE: PFE): Presentation of data on Bavencio in bladder cancer
  • CELYAD SA/ADR (NASDAQ: CYAD): Phase 1 data on CYAD-101 in colorectal cancer
  • Immunomedics, Inc. (NASDAQ: IMMU): Phase 2 data on sacituzumab govitecan in urothelial cancer
  • Xencor Inc (NASDAQ: XNCR): initial Phase 1 data on XmAb20717 in solid tumors
  • MacroGenics Inc (NASDAQ: MGNX): Phase 1 data on MGD013 in solid tumors; Phase 1/2 data for MGC018 in solid tumors
  • DelMar Pharmaceuticals Inc (NASDAQ: DMPI): Phase 2 data on VAL-083 in unmethylated newly diagnosed glioblastoma multiforme
  • Salarius Pharmaceuticals Inc (NASDAQ: SLRX): Phase 1 data on seclidemstat in Ewing sarcoma
  • AstraZeneca: Phase 3 data on Tagrisso in non-small cell lung carcinoma
  • Genocea Biosciences Inc (NASDAQ: GNCA): updated Phase 1/2 data on GEN-009 vaccine for various cancers
  • NextCure Inc (NASDAQ: NXTC): Phase 1 biomarker data on NC318 in solid tumors
  • Spring Bank Pharmaceuticals Inc (NASDAQ: SBPH): Phase 1 data on SB 11285 in solid tumors
  • Adaptimmune Therapeutics PLC – ADR (NASDAQ: ADAP): Summary of Phase 1 data on MAGE-A4 in solid tumors
  • ZIOPHARM Oncology Inc. (NASDAQ: ZIOP): initial Phase 2 data on Ad-RTS-hIL-12, along with veledimex and Libtayo in refractory glioblastoma multiforme
  • Agios Pharmaceuticals Inc (NASDAQ: AGIO): Phase 1 data on vorasidenib in IDHm low-grade glioma
  • Oncternal Therapeutics Inc (NASDAQ: ONCT): updated Phase 1/2 data on cirmtuzumab and ibrutinib in chronic lymphocytic leukemia and mantle cell lymphoma
  • Roche Holdings AG Basel ADR Common Stock (OTC: RHHBY): Phase 2 data on tiragolumab and atezolizumab in non-small cell lung cancer
  • Aptose Biosciences Inc (NASDAQ: APTO): Phase 1 data on CG-806 in chronic lymphocytic leukemia or non-Hodgkin lymphomas
  • Kura Oncology Inc (NASDAQ: KURA): Phase 2 mature data on tipifarnib in head and neck squamous cell carcinomas with HRAS Mutations
  • Innate Pharma SA (NASDAQ: IPHA): Phase 2 second cohort expansion data on monalizumab in combination with cetuximab in squamous cell carcinoma of the head and neck
  • Imv Inc (NASDAQ: IMV):: updated Phase 1b data on DPX-Survivac and epacadostat in ovarian cancer
  • MEI Pharma Inc (NASDAQ: MEIP): updated Phase 1b data on ME-401 in relapsed/refractory follicular lymphoma/chronic lymphocytic leukemia
  • TapImmune Inc. common stock (NASDAQ: MRKR): updated Phase 1/2 data on MultiTAA-Specific T Cells in pancreatic cancer
  • Inovio Pharmaceuticals Inc (NASDAQ: INO):: Phase 1/2 12-month overall survival data on INO-5401 in glioblastoma

ISCT Presentations

Mesoblast limited (NASDAQ: MESO): oral presentation of results using its allogeneic mesenchymal stem cell product candidate remestemcel-L in patients with inflammatory lung disease

ASCP Presentations

Karuna Therapeutics Inc (NASDAQ: KRTX) will present additional data from the Phase 2 clinical trial of KarXT for the treatment of acute psychosis in patients with schizophrenia.



  • REDHILL BIOPHAR/S ADR (NASDAQ: RDHL) (before the market open)
  • Trinity Biotech plc (NASDAQ: TRIB) (before the market open)


  • Adverum Biotechnologies Inc (NASDAQ: ADVM) (after the close)
  • Geron Corporation (NASDAQ: GERN) (after the close)

IPO Quiet Period Expiry

Lyra Therapeutics Inc (NASDAQ: LYRA)

Correction: Clovis Oncology Inc's (NASDAQ: CLVS) Phase 1b/2 data on the Opdivo-lucitanib combo is due at a medical meeting in fall of 2020.


Related Articles (AZN + MRK)

View Comments and Join the Discussion!

Posted-In: Biotech News Penny Stocks Health Care Previews FDA Trading Ideas General Best of Benzinga